Vaccines (Aug 2024)

Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis

  • Annalisa Rosso,
  • Maria Elena Flacco,
  • Giovanni Cioni,
  • Marco Tiseo,
  • Gianmarco Imperiali,
  • Alessandro Bianconi,
  • Matteo Fiore,
  • Giovanna Letizia Calò,
  • Vittorio Orazi,
  • Anastasia Troia,
  • Lamberto Manzoli

DOI
https://doi.org/10.3390/vaccines12090969
Journal volume & issue
Vol. 12, no. 9
p. 969

Abstract

Read online

Several vaccines against chikungunya fever have been developed and tested, and one has been recently licensed. We performed a meta-analysis to estimate the immunogenicity and safety of all chikungunya vaccines that have been progressed to clinical trial evaluation (VLA1553; mRNA-1388/VAL-181388; PXVX0317/VRC-CHKVLP059-00-VP; ChAdOx1 Chik; MV-CHIK). We included trials retrieved from MedLine, Scopus, and ClinicalTrials.gov. The outcomes were the rates of seroconversion/seroresponse and serious adverse events (SAEs) after the primary immunization course. We retrieved a total of 14 datasets, including >4000 participants. All candidate chikungunya vaccines were able to elicit an immunogenic response in ≥96% of vaccinated subjects, regardless of the vaccination schedule and platform used, and the seroconversion/seroresponse rates remained high 6 to 12 months after vaccination for most vaccines. Four of the five candidate vaccines showed a good overall safety profile (no data were available for ChAdOx1 Chik), with no significant increase in the risk of SAEs among the vaccinated, and a low absolute risk of product-related SAEs. Overall, the present findings support the potential use of the candidate vaccines for the prevention of chikungunya and the current indication for use in adult travelers to endemic regions of the licensed VLA 1553 vaccine. In order to extend chikungunya vaccination to a wider audience, further studies are needed on individuals from endemic countries and frail populations.

Keywords